Sandu Pharmaceuticals Reports FY26 Net Profit of Rs. 176.61 Lakhs; Recommends Rs. 1 Per Share Dividend

Sandu Pharmaceuticals Limited approved its standalone audited financial results for the quarter and year ended 31st March 2026 at a Board of Directors meeting held on 5th May 2026. The results, reviewed by the Audit Committee and approved by the Board, were prepared in accordance with Indian Accounting Standards (Ind AS) under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company operates in a single business segment — Ayurvedic Proprietary Medicines — as evaluated by management.

Full-Year Financial Performance

Sandu Pharmaceuticals posted a net profit of Rs. 176.61 lakhs for the year ended 31st March 2026, compared to Rs. 154.89 lakhs in the year ended 31st March 2025, reflecting year-on-year growth. Revenue from operations rose to Rs. 6993.45 lakhs from Rs. 6719.24 lakhs in the prior year. Total income for FY26 stood at Rs. 7037.89 lakhs against Rs. 6735.99 lakhs in FY25. Profit before tax for the full year came in at Rs. 265.54 lakhs, up from Rs. 215.58 lakhs in the previous year. Total comprehensive income for the year was Rs. 242.95 lakhs compared to Rs. 219.47 lakhs in FY25.

Metric: Year ended 31st March 2026 Year ended 31st March 2025 Revenue from Operations: Rs. 6993.45 lakhs Rs. 6719.24 lakhs Total Income: Rs. 7037.89 lakhs Rs. 6735.99 lakhs Total Expenses: Rs. 6772.35 lakhs Rs. 6520.41 lakhs Profit Before Tax: Rs. 265.54 lakhs Rs. 215.58 lakhs Net Profit: Rs. 176.61 lakhs Rs. 154.89 lakhs Total Comprehensive Income: Rs. 242.95 lakhs Rs. 219.47 lakhs Basic EPS (Rs.): 1.83 1.60 Diluted EPS (Rs.): 1.83 1.60

Quarterly Financial Highlights

For the quarter ended 31st March 2026, the company reported revenue from operations of Rs. 1685.34 lakhs, compared to Rs. 1406.92 lakhs in the corresponding quarter of the previous year. Net profit for Q4 FY26 stood at Rs. 4.34 lakhs, against Rs. 32.64 lakhs in Q4 FY25. Profit before tax for the quarter was Rs. 74.71 lakhs versus Rs. 34.24 lakhs in the same period last year. Total comprehensive income for the quarter was Rs. 70.68 lakhs compared to Rs. 42.48 lakhs in the corresponding quarter.

Metric: Q4 FY26 (31st March 2026) Q3 FY26 (31st December 2025) Q4 FY25 (31st March 2025) Revenue from Operations: Rs. 1685.34 lakhs Rs. 1876.09 lakhs Rs. 1406.92 lakhs Total Income: Rs. 1721.85 lakhs Rs. 1877.46 lakhs Rs. 1413.85 lakhs Profit Before Tax: Rs. 74.71 lakhs Rs. 85.50 lakhs Rs. 34.24 lakhs Net Profit: Rs. 4.34 lakhs Rs. 97.51 lakhs Rs. 32.64 lakhs Total Comprehensive Income: Rs. 70.68 lakhs Rs. 114.47 lakhs Rs. 42.48 lakhs

Balance Sheet and Cash Flow Position

As at 31st March 2026, total assets stood at Rs. 5586.93 lakhs compared to Rs. 5571.87 lakhs as at 31st March 2025. Equity share capital remained unchanged at Rs. 966.10 lakhs, while other equity increased to Rs. 3401.23 lakhs from Rs. 3235.62 lakhs. Cash and cash equivalents at the end of the year rose significantly to Rs. 590.77 lakhs from Rs. 130.39 lakhs at the beginning of the year. Net cash flow from operating activities for FY26 was Rs. 611.58 lakhs, compared to Rs. 95.04 lakhs in FY25. The company reported zero outstanding borrowings as at 31st March 2026.

Dividend Recommendation and Auditor Appointments

The Board recommended a final dividend of Rs. 1 per equity share (i.e., 10% on paid-up share capital) having a face value of Rs. 10/- each for the financial year ended 31st March 2026, subject to shareholder approval at the ensuing Annual General Meeting. The record date, book closure, and dividend payment date will be communicated in due course. The statutory auditors, M/s Dileep and Prithvi, Chartered Accountants (Firm No. 122290W), issued an unmodified audit opinion on the standalone financial results for the quarter and year ended 31st March 2026.

Key Corporate Decisions at Board Meeting

The Board also took several other decisions at its meeting held on 5th May 2026:

Cost Auditor Reappointment: M/s Shekhar Joshi & Co (Registration No. 100448), Cost Accountants, were reappointed as Cost Auditor of the company for the financial year 2026-27.

Internal Auditor – Goa Plant: M/s Akhil Pai & Co was reappointed as Internal Auditor for Goa Plant Operations for FY 2026-27.

Internal Auditor – Mumbai: M/s Uday & Uday Associates, Chartered Accountants, was reappointed as Internal Auditor for Mumbai operations for FY 2026-27.

Statement of Utilizations and Deviations: The Board took note of the Statement of Utilizations and Deviations as per Regulation 32 of SEBI (LODR) Regulations 2015 for the quarter ended 31st March 2026.

Large Corporate Disclosure: The company confirmed it does not qualify as a Large Corporate under the applicable SEBI framework, and accordingly, the Annual Disclosure under Annexure B2 is not required.

Sandu Pharmaceuticals Limited has completed the mandatory newspaper publication of its unaudited standalone financial results for the third quarter of FY26 ended 31st December 2025, in compliance with SEBI (LODR) Regulations 2015. The company published its financial results in "Navprabha" and "Navhind Times" newspapers dated 7th February 2026, following board approval on 6th February 2026.

Regulatory Compliance and Publication

The company submitted newspaper cuttings to the Bombay Stock Exchange Limited through a formal communication dated 7th February 2026. Company Secretary Pratika Mhambray signed the compliance letter, confirming that the financial results were published as required under Regulation 30 of SEBI (LODR) 2015.

Compliance Parameter: Details Publication Date: 7th February 2026 Newspapers: Navprabha and Navhind Times Board Approval Date: 6th February 2026 Regulation: SEBI (LODR) 2015 - Regulation 30

Q3FY26 Financial Performance

The published results demonstrate strong financial performance for Q3FY26, with net profit reaching ₹97.51 lakhs compared to ₹55.55 lakhs in Q3FY25. Revenue from operations stood at ₹1876.09 lakhs for Q3FY26, showing consistent operational performance.

Financial Metric: Q3FY26 Q3FY25 Change Total Income: ₹1877.46 lakhs ₹1839.74 lakhs Growth Net Profit After Tax: ₹97.51 lakhs ₹55.55 lakhs 75.5% increase Basic EPS: ₹1.01 ₹0.57 Improved Equity Share Capital: ₹966.10 lakhs ₹966.10 lakhs Stable

Nine-Month Performance Summary

For the nine-month period ended 31st December 2025, the company reported total income of ₹5316.04 lakhs and net profit of ₹172.27 lakhs. Basic earnings per share for the nine-month period stood at ₹1.78 compared to ₹1.27 in the previous year.

Corporate Governance

The financial results were reviewed by the audit committee and approved by the board of directors. The company maintains compliance with Indian Accounting Standards (Ind AS) and SEBI regulations. Complete financial results are available on the company's website www.sandu.in and stock exchange websites.

Source: Newspaper Publication Documents

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.